[1]刘瑞磊 狄金明 陈健宁 陆敏华 方友强.PARP-1与前列腺癌临床因素的相关性及生存分析[J].中华腔镜泌尿外科杂志(电子版),2015,(06):447-450.[doi:10.3877/cma.j.issn.1674-3253.2015.06.015 ]
　Liu Ruilei,Di Jinming,Chen Jianning,et al.The correlation between PARP-1 expression level and clinical features of prostate cancer patients and survival analysis[J].,2015,(06):447-450.[doi:10.3877/cma.j.issn.1674-3253.2015.06.015 ]
点击复制

PARP-1与前列腺癌临床因素的相关性及生存分析()
分享到：

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2015年06期
页码:
447-450
栏目:
实验研究
出版日期:
2015-12-31

文章信息/Info

Title:
The correlation between PARP-1 expression level and clinical features of prostate cancer patients and survival analysis
作者:
刘瑞磊 1狄金明 2陈健宁 3陆敏华 2方友强 2
510630 广州，中山大学附属第三医院甲乳外科1，泌尿外科2，病理科3
Author(s):
Liu Ruilei1;  Di Jinming2;  Chen Jianning3;  Lu Minhua2;  Fang Youqiang2.
Department of Urology, 3Department of Pathology, the Third Affiliated Hospital of Sun Yet-sen University, Guangzhou 510630, China
关键词:
PARP-1; 免疫组化; 前列腺肿瘤
DOI:
10.3877/cma.j.issn.1674-3253.2015.06.015
摘要:
目的本研究通过分析多聚腺苷二磷酸核糖聚合酶（ PARP-1）在前列腺癌及前列腺增生组织中的表达差异，探讨其与其他临床指标的相关性，并分析与前列腺癌预后的相关性。方法检测 126例前列腺癌组织及 83例前列腺增生组织中 PARP-1的表达情况，比较分析实验组与对照组之间 PARP-1表达的差异，以及实验组 PARP-1表达水平与其他临床指标的相关性，并分析 PARP-1与前列腺癌预后的相关性。结果前列腺癌组 PARP-1的阳性表达率（ 38.9%）显著高于前列腺增生组（ 10.8%）（P＜0.05）。PARP-1表达水平与其他临床病理指标的相关性分析结果显示，PARP-1表达水平与临床分期密切相关（ P＜0.05）；但与年龄及 Gleason评分无明显相关性（ P＞0.05）。生存分析显示，PARP-1蛋白表达水平高的前列腺癌患者预后较低表达水平的患者差（ P＜0.05）。结论 PARP-1在前列腺癌组织中的表达较前列腺增生组织中明显增高，且随着临床分期的增高而表达增强，其高表达的患者预后较差，表明其可能在前列腺癌的发生发展中发挥重要作用。

参考文献/References:

[1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics,2014 [M]. CA Cancer J Clin, 2014, 64(1): 9-29.
[2] Elliott B, Jasin M. Double-strand breaks and translocations in cancer[J]. Cell Mol Life Sci, 2002, 59(2): 373-385.
[3] Michor F. Chromosomal instability and human cancer [J]. Philos Trans R Soc Lond B Biol Sci, 2005, 360(1455): 631-635.
[4] Sodhi RK, Singh N, Jaggi AS. Poly (ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications [J]. Vascul Pharmacol, 2010, 53(3-4): 77-87.
[5] Schreiber V, Dantzer F, Ame JC, et al. Poly (ADP-ribose): novel functions for an old molecule [J]. Nat Rev Mol Cell Biol, 2006, 7 (7): 517-528.
[6] Slade D, Dunstan MS, Barkauskaite E, et al. The structure and catalytic mechanism of a poly (ADP-ribose) glycohydrolase [J]. Nature, 2011, 477(7366): 616-620.
[7] Pellicciari R, Camaioni E, Costantino G. 3. Life or death decisions: the cast of poly(ADP-ribose)polymerase (PARP) as a therapeutic target for brain ischaemia[J]. Prog Med Chem, 2004, 42: 125-69.
[8] Brustmann H. Poly (adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome [J]. Int J Gynecol Pathol, 2007, 26 (2): 147-153.
[9] Bieche I, de Murcia G, Lidereau R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer[J]. Clin Cancer Res, 1996, 2(7): 1163-1167.
[10] Rojo F, García-Parra J, Zazo S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer[J]. Ann Oncol, 2012, 23(5): 1156-1164.
[11] Shimizu S, Nomura F, Tomonaga T, et al. Expression of poly (ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance[J]. Oncol Rep, 2004, 12(4): 821-825.
[12] Nosho K, Yamamoto H, Mikami M, et al. Overexpression of poly (ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis [J]. Eur J Cancer, 2006, 42 (14): 2374-2381.
[13] Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma[J]. Am J Hematol, 1991, 37(4): 223-227.
[14] Galia A, Calogero AE, Condorelli R, et al. PARP-1 protein expression in glioblastoma multiforme[J]. Eur J Histochem, 2012, 56(1): e9.
[15] Salemi M, Galia A, Fraggetta F, et al. Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue[J]. Eur J Histochem, 2013, 57(2): e13.
[16] Ossovskaya V, Koo IC, Kaldjian EP, et al. Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in Triple-Negative breast cancer and other primary human tumor types [J]. Genes Cancer, 2010, 1(8): 812-821.

相似文献/References:

[1]黄文涛,周祥福,冯志英.Survivin 在膀胱移行细胞癌中的表达及其临床意义[J].中华腔镜泌尿外科杂志(电子版),2008,(01):59.
　HUANG Wen-tao,ZHOU Xiang-fu,FENG Zhi-ying.The expression and clinic effect of survivin in bladder transitional cell cancer[J].,2008,(06):59.
[2]金亦,唐录英,刘勇,等.肾炎症性肌纤维母细胞瘤临床病理分析[J].中华腔镜泌尿外科杂志(电子版),2011,(06):477.
　JIN Yi,TANG Lu-ying,LIU Yong,et al.Inflammatory myofibroblastic tumor of the kidney:a clinicopathologic study[J].,2011,(06):477.
[3]黄海,卢振权,杜涛,等.碳酸酐酶Ⅸ(CA-Ⅸ)与HIF-1α在前列腺癌中的表达情况及相关性研究[J].中华腔镜泌尿外科杂志(电子版),2012,(05):60.
　HUANG Hai,LU Zhen-quan,DU Tao,et al.The expression and correlation studies about Carbon anhydrase Ⅸ (CA-Ⅸ) and Hypoxia-inducible factor-1 alpha in prostate cancer[J].,2012,(06):60.
[4]徐汉新 陈华忠 吴兆春 刘文彬 杨邦彦 黄海.紧密连接蛋白 Zo-1和 Occludin在间质性膀胱炎中的表达及其作用的研究[J].中华腔镜泌尿外科杂志(电子版),2014,(04):289.[doi:10.3877/cma.j.issn.1674-3253.2014.04.014 ]
　Xu Hanxin*,Chen Huazhong,Wu Zhaochun,et al.The expression and effect of Zo -1 and Occludin in interstitial cystitis[J].,2014,(06):289.[doi:10.3877/cma.j.issn.1674-3253.2014.04.014 ]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金青年基金项目（81202012），广东省科技计划社会发展领域科技计划项目
通讯作者：方友强，Email：Fang1573@hotmail.com
更新日期/Last Update: 1900-01-01